Quizartinib
| Quizartinib | |
|---|---|
 | |
| Identifiers | |
| CAS number | 950769-58-1 |
| Jmol-3D images | Image 1 |
| Properties | |
| Molecular formula | C29H32N6O4S |
| Molar mass | 560.67 g mol |
 (what is this?) (verify)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor that is currently under development for the treatment of acute myeloid leukaemia. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene. Flt3 mutations are among the most common mutations in acute myeloid leukaemia due to of Flt3. The presence of this mutation is a marker of adverse outcome.
Specifically, Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs).
Mutations cause constitutive action of Flt3 leading to resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.
References
Retrieved from : http://en.wikipedia.org/wiki/Quizartinib
